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Isoprenoid synthetic pathway inhibitors and farnesyl transferase
inhibitors represent a new class of anticancer drugs, very promising
to block the tumour growth without important toxicity. Among these
molecules sodium phenylacetate (NaPa), a product of phenylalanine
metabolism, has been shown to induce cytostasis (Prasanna et al,
1995) and differentiation in a variety of tumour models (Samid et al,
1992a, 1992b). Thus, it was previously shown by us and others that
NaPa treatment can induce tumour cell apoptosis alone (Adam et al,
1995) or in association with tamoxifen (Adam et al, 1997). These
antiproliferative molecules induce DNA fragmentation, cytochrome
C release and caspase 3 activation preferentially in ras transformed
cells (Suzuki et al, 1998). In vivo studies on animal models demon-
strated an antitumoral effect of NaPa and derivatives. Thus, MCF-7
ras tumour development in nude mice was blocked by NaPa treat-
ment (Adam et al, 1995). This NaPa antitumoral activity can be
related not only to antiproliferative effect on MCF-7 ras but also to
stromal paracrine effects. In this context, we have shown that NaPa
treatment modulated the synthesis and secretion of autocrine and
paracrine growth factors secreted by MCF-7 ras cells (Thibout et al,
1998). In our in vivo previous study, we have observed that NaPa
induced, in mammary MCF-7 ras tumours, a stroma development, a
tumour angiogenesis reduction and a decrease of cell invasiveness
in adjacent tissues (Adam et al, 1997). These observations led us to
investigate the u-PA/u-PAR protease system clearly involved in the
pericellular proteolysis necessary to tumour cell migration (Holst-
Hansen et al, 1996). Tumour cell adhesion to extracellular-matrix
(ECM) proteins was also shown to be important for the tumour
invasive process (Tatsumi et al, 1996). Among these proteins, we
focused our attention on fibronectin, a major protein found in almost
all the tissues, and vitronectin which uses u-PAR as a receptor
(Carriero et al, 1997). In order to become more invasive, tumour
cells must stabilize adhesive interactions that prevent detachment at
secondary sites. Intercellular adhesion molecules like ICAM-1,
LFA-1 and MAC-1 (CD11b) were shown to be associated with
phenotypes of various tumour cell types (Hayashi et al, 1997). For
these reasons, we investigated these 3 adhesion molecules in 3 cell
lines, representative of 3 different phenotypes (MCF-7, MCF-7 ras
and MDA-MB-231) treated with increasing concentrations of NaPa. 
MATERIALS AND METHODS 
Antibodies and reagents 
The monoclonal antibody (mAb) to u-PA which recognizes 
the a-chain of u-PA (#3639) was from American Diagnostica
(Greenwich, USA). Fluorescein isothiocyanate-labelled 
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Summary Sodium phenylacetate (NaPa), a non-toxic phenylalanine metabolite, has been shown to induce in vivo and in vitro cytostatic
and antiproliferative effects on various cell types. In this work, we analysed the effect of NaPa on the invasiveness of breast cancer cell (MDA-
MB-231, MCF-7 and MCF-7 ras). Using the highly invasive breast cancer cell line MDA-MB-231, we demonstrated that an 18-hour incubation
with NaPa strongly inhibits the cell invasiveness through Matrigel (86% inhibition at 20 mM of NaPa). As cell invasiveness is greatly
influenced by the expression of urokinase (u-PA) and its cell surface receptor (u-PAR) as well as the secretion of matrix metalloproteinases
(MMP), we tested the effect of NaPa on these parameters. An 18-hour incubation with NaPa did not modify u-PA expression, either on MDA-
MB-231 or on MCF-7 and MCF-7 ras cell lines, and induced a small u-PA decrease after 3 days of treatment of MDA-MB-321 with NaPa. In
contrast, an 18 h incubation of MDA-MB-231 increased the expression of u-PAR and the secretion of MMP-9. As u-PAR is a ligand for
vitronectin, a composant of the extracellular matrix, these data could explain the increased adhesion of MDA-MB-231 to vitronectin, while cell
adhesivity of MCF-7 and MCF-7 ras was unmodified by NaPa treatment. NaPa induced also an increased expression of both Lymphocyte
Function-Associated-1 (LFA-1) and Intercellular Adhesion Molecule-1 (ICAM-1), which was obvious from 18 hour incubation with NaPa for the
MDA-MB-231 cells, but was delayed (3 days) for MCF-7 and MCF-7 ras. Only neutralizing antibodies against LFA-1 reversed the decreased
invasiveness of NaPa-treated cells. Therefore we can conclude that the strong inhibition of MDA-MB-231 invasiveness is not due to a
decrease in proteases involved in cell migration (u-PA and MMP) but could be related both to the modification of cell structure and an
increased expression of adhesion molecules such as u-PAR and LFA-1. © 2001 Cancer Research Campaign http://www.bjcancer.com
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F(ab¢)2 fraction of goat anti-mouse IgG1 were from Immunotech
(Marseille, France). The FITC-labelled mAb to ICAM-1 (CD104)
was from R&D Systems (Abington, UK) and the FITC-labelled
F(ab¢)2 fraction of swine anti-rabbit were purchased from Dako
(Trappes, France). Non-labelled mAb antibodies to CD104 (R&D
Systems) and LFA-1 (Immunotech) were used for neutralizing
assays. The polyclonal antibody to PAI-1 was kindly provided by R
Lijnen (Leuven, Belgium). Vitronectin was from Serbio laboratories
(Gennevilliers, France), fibronectin was from Sigma (St Louis, USA)
and NaPa from SERATEC (France). 
Cell cultures 
MDA-MB-231 were cultured in RPMI 1640 (Eurobio, les Ulis,
France) supplemented with 10% fetal calf serum (FCS), 1 mM 
L-glutamine, 100 IU ml–1 penicillin, 100 mg ml–1 streptomycin
(Gibco Brl, NY, USA) MCF-7 and MCF-7 ras were cultured in
DMEM supplemented with FCS (10%), L-glutamine (2 mM), and
antibiotics as above. 
Cell invasiveness through Matrigel  
8-mm-diameter pore Transwell (Dutcher, Brumath, France) were
coated with 500 ml of Matrigel (Beckton-Dickinson Europe,
Meylan, France) diluted at 100 mg ml21. Breast tumour cells were
detached with trypsin (0.05%, w/v) (Sigma), washed twice with
phosphate buffer saline (PBS) (Eurobio) and 2 ´ 105 cells in RPMI
1640 with 0.2 mg ml21 bovine serum albumin (BSA) (Sigma)
were seeded in the upper chamber of the Matrigel-coated insert.
The lower chamber was filled with 1 ml of RPMI 1640 together
with 2 mg ml21 BSA and 20 ng ml21 basic fibrobast growth factor
(bFGF) (R&D Systems). After 18 hours of incubation, the non-
migrated cells in the upper chamber were gently scraped, and the
adherent cells present on the lower surface of the insert were
coloured by May-Grünewald-Giemsa and counted by light
microscopy, 10 fields (magnification 3200) were counted for each
insert. For neutralizing assay, the cells were incubated for 30 min
at 4˚C with 100 mg of the neutralizing mAb before being seeded in
the upper chamber of the insert. Controls were incubated with an
irrelevant IgG1 antibody (Immunotech) at the same concentration. 
Flow cytometry analysis 
Flow cytometry analysis were performed on non-permeabilized
cells, as previously described (Paysant et al, 1998). ICAM-1
(CD104), LFA-1 (CD11a) and MAC-1 (CD11b) expression on
breast cancer cells were determined by direct immunofluores-
cence, while u-PA and PAI-1 were detected by indirect immuno-
fluorescence. Tumour cells were detached by a non-enzymatic cell
dissociation solution (Sigma) and the cells were washed twice in
cold PBS. Approximately 5 ´ 105 cells were incubated for 15
minutes at 4˚C with 10 ml of the specific antibodies (1 mg ml21).
After 2 washes, the cell suspension was immediately analysed in a
flow cytometer (EPICS XL-MCL, Coulter, USA) when antibody
were directly conjugated to FITC, while another 15 minutes in-
cubation with a FITC anti-mouse IgG1 antibody or an anti-rabbit
antibody (10 mg ml21) was carried out respectively for the detec-
tion of u-PA and PAI-1 antibody before cytometry analysis. Data
are expressed either as the percentage of fluorescent cells or as the
specific mean channel fluorescence intensity (MFI). Specific MFI
was calculated for each sample by subtracting the background MFI
produced by an irrelevant antibody from the MFI value generated
by the specific antibody. 
Measurement of u-PAR antigen 
The adherent cells were washed twice with PBS and lysed in PBS
containing 0.1% Triton X-100 and sonicated (Vibracell Bioblock,
Illkirch, France) at 60 Hz for 20 seconds. u-PAR antigen in the
lysates was measured by an ELISA assay (Imubind kit u-PAR,
American Diagnostica), according to the manufacturer’s instruc-
tions. The proteins in the cell lysates were assayed by the method
of Bradford (1976). Results were expressed in ng of u-PAR
mg21 of proteins. 
SDS-polyacrylamide gel electrophoresis zymography 
Electrophoresis was performed either on 5 ml of conditioned
medium or on 7 mg proteins of the lysate, in 7.5% polyacrylamide
gels containing 10% sodium dodecyl sulphate (SDS) and gelatin (1
mg ml21) under non-reducing conditions. After electrophoresis,
SDS was removed from gels by washing for 1 hour in 2.5% Triton
X-100 at room temperature. Gelatinase activity was revealed
overnight in a buffer containing 50 mM Tris-HCl, 5 mM CaCl2,
pH 7.6. The gels were stained with Coomassie blue R250 (0.25%)
and gelatinolytic activity was evidenced as clear bands against the
blue background of stained gelatin. 
Adhesion assay 
Adhesion assay was performed as previously described (Paysant et
al, 1998), with minor modifications. Tissue culture plates (96
wells) were prepared as follows: 50 ml per well of vitronectin
(0.5 mg ml21) or fibronectin (100 mg ml21) were incubated
overnight at 4˚C. Following incubation, plates were washed in
PBS and non-specific binding sites were blocked with 1% BSA in
PBS for 2 hours at 37˚C. Plates were then washed twice in PBS
prior to the plating of the cells. Tumour cells were detached by
trypsin (0.05%, w/v), washed twice in PBS and 100 ml of a
23106 ml21 cell suspension were placed per well in triplicate in
vitronectin or fibronectin coated wells. After a 2 hour incubation,
non-adherent cells were removed by 3 rinses in PBS, and adherent
cells were quantified by their acid phosphatase activity on parani-
trophenyl phosphate (1 mg ml21) in sodium acetate buffer pH 5.5.
After 6 h the reaction was stopped with NaOH 1N and measure-
ment of absorbance at 405 nm was performed in an automated
plate reader (Dynatech, Saint Quentin, France). 
Statistical analysis 
Statistical significance was determined by the ANOVA test using
the InStat Software (Sigma). 
RESULTS 
Effect of NaPa on the invasiveness of MCF-7, MCF-7 ras
and MDA-MB-231 cells 
In order to investigate the effect of NaPa on the tumour invasive
processes, we have compared on one hand the invasiveness of 3
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cell lines with different phenotypes and on the other hand the u-PA
and u-PAR system involved in the invasivity of mammary tumour
cells. Under our conditions, MCF-7 and MCF-7 ras were weakly
invasive in Matrigel test. This is in agreement with other reports
(Holst-Hansen et al, 1996; Hazan et al, 2000). In contrast, under
the same conditions MDA-MB-231 cells were highly invasive. In
8 m Transwell coated with Matrigel, 7% of MDA-MB-231 cells
migrated after 18 h of incubation. In the presence of increasing
concentrations of NaPa, this migration was dose dependently
inhibited (Figure 1). With 2.5 mM NaPa the percentage of migrat-
ory cells was reduced to 29.5% and for higher NaPa concentra-
tions, NaPa inhibited almost totally the invasion (86% inhibition
for 20 mM). Consequently, we investigated u-PA and its receptor
(u-PAR) as well as its inhibitor, Plasminogen Activator Inhibitor-1
(PAI-1) which are clearly responsible for tumoral cell invasion. 
Effect of NaPa on u-PA expression in MCF-7, MCF-7 ras
and MDA-MB-231 cells 
The percentage of u-PA positive cells, analysed by flow cytometry,
was very different according to the cancer cell types. u-PA was
highly expressed in most of MDA-MB-231 cells (94.8% of posi-
tive cells) as compared to MCF-7 cells (14.4%) and MCF-7 ras
cells (24.3%) (Table 1). Despite the decrease of cell invasiveness,
the NaPa treatment of MDA-MB-231, for 18 h, did not modify the
expression of u-PA. Only a 3-day treatment with NaPa at 20 mM
reduced the u-PA expression, from 94.8% to 48% of positive cells,
and the amount of u-PA expressed by positive cells was reduced to
36.2% (Figure 2). This decrease was highly significant (P < 0.001).
In contrast, the same NaPa treatment, even after 3 days, did not
affect the u-PA expression in MCF-7 and MCF-7 ras cells (data not
shown). Whereas MCF-7 and MCF-7 ras do not contain signif-
icant amount of PAI-1, this inhibitor is synthetized by MDA-MB
231 and more than 50% of MDA-MB-231 cells expressed PAI-1 at
their surface. NaPa treatment had no effect neither on PAI-1
secreted in the medium nor on PAI-1 expressed at cell membrane
(data not shown). 
Effect of NaPa on MMP-9 secretion by MCF-7, MCF-7
ras and MDA-MB-231 cells 
Despite the decrease in cell invasiveness through Matrigel by
NaPa treatment, the amount of MMP-9 either in the conditioned
medium or in cell lysates of MDA-MB-231 was increased when
treated with NaPa (Figure 3). In our working conditions, we were
unable to detect significant amount of MMP in the conditioned
medium or in the lysate of MCF-7 and MCF-7 ras cells (data not
shown). 
Figure 1 Effect of increasing concentrations of NaPa on MDA-MB-231
invasiveness through Matrigel. MDA-MB-231 were treated for 18 hours by
increasing concentrations of NaPa. After trypsination and 2 washes in PBS,
2 ´ 105 cells were added in Transwell coated with Matrigel and bFGF 
(20 ng/ml) was present in the lower part of the invasion chamber (see
Materials and Methods section). After an 18 hour incubation at 37˚C, the cells
in the upper part of the invasion chamber were gently detached, and cells
which had traversed the filter (pore 8 m) were counted by light microscopy
after May-Grünewald coloration. 10 fields (magnification 3200) were counted
for each insert. 
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Table 1 Expression of uPA and cell adhesion molecules (ICAM-1, LFA-1,
MAC-1) on MDA-MB-231, MCF-7 and MCF-7 ras cells 
% of positive cells 
MDA-MB-231 MCF-7  MCF-7ras 
uPa 94.8±4.1 14.4±3.8 24.3±5.3 
ICAM-1 78.8±4.5  15.6±5.5  36±4.8 
LFA-1 40±5.2 28.3±5  9.6±3.8 
MAC-1 11±1.1  5.9±1.5  4.4±1.2 
These different molecules were detected by flow cytometry. For each antigen
analysed the percentage of positive cells was recorded.
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Figure 2 Effect of increasing concentrations of NaPa on the expression of
uPA at the surface of MDA-MB-231. MDA-MB-231 were incubated for
18 hours or 3 days with increasing concentrations of NaPa, and uPA
expressed at the membrane was analysed by flow cytometry. The Mean
Fluorescence Intensity (MFI) represents the mean intensity of labelling of the
positive cells. u-PA was detected by indirect immunofluorescence using a
FITC-conjugated antimouse antibody. Data are expressed as the percentage
(as compared to the controls) of the MFI ± SEM of 3 separate experimentsEffect of NaPa on the u-PAR content of MCF-7, MCF-7
ras and MDA-MB-231 cells 
The total amount of u-PAR was measured by ELISA, using an
antibody which recognizes both free and u-PA associated u-PAR.
MCF-7 and MCF-7 ras have relatively low amounts of u-PAR
(respectively 0.52 ± 0.07 and 0.41 ± 0.04 ng mg21 proteins) as
compared to MDA-MB 231 (5.3 ± 1.04 ng mg21 of proteins). A
NaPa treatment of 18 h increased dose-dependently the amount of
u-PAR in MDA-MB-231 cells whereas it did not change those of
MCF-7 and MCF-7 ras cells, even after 3 days (Table 2). 
Effect of NaPa on tumour cell adhesion to extracellular
matrix proteins 
After 18 h of treatment with 20 mM NaPa, MDA-MB-231 cells
take a spindle-shape and detached from the plastic surface. Despite
this change of morphology, the viability of the adherent cells was
unaltered, as estimated by the blue trypan exclusion test or the
absence of increased incorporation of propidium iodide. Lower
concentrations did not significantly modify cell shape or adhe-
sivity. In contrast, NaPa treatment did not modify significantly the
adhesion and the morphology of MCF-7 and MCF-7 ras cells (data
not shown). Since tumour cells express receptors for fibronectin
and vitronectin (among them u-PAR) which are extracellular
matrix proteins present in tumours (Loridon-Rosa et al, 1988), we
compared the adhesivity of the 3 cell lines to these proteins. The
cell adhesivities of the 3 cell lines were similar. On vitronectin, an
18 h NaPa treatment increased significantly (P = 0.002) the MDA-
MB-231 cell adhesion (Figure 4), whereas it had no effect on the
adhesion of MCF-7 and MCF-7 ras cells (data not shown). On
fibronectin, NaPa, even at high concentrations, did not modify the
adhesion of the 3 cell types (data not shown). 
Effect of NaPa on cell adhesion LFA-1, MAC-1 and
ICAM-1 molecules 
We compared the 3 cancer cell phenotypes for the expression of
these integrins involved in the tumour cell adhesion. The expression
of MAC-1 was low in the 3 cell types and only a small percentage of
cells were positive for this antigen. As already observed for u-PAR,
the expression of MAC-1, LFA-1 and ICAM-1 was higher in MDA-
MB 231 cells than in MCF-7 and MCF-7 ras (Table 1). An 18 h
Decrease of breast cancer cell invasiveness by NaPa 805
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Figure 3 Analysis of metalloproteinases secreted in conditioned medium or
lysates of MDA-MB-231. MDA-MB-231 were incubated in serum-free
medium for 48 hours with increasing concentrations of NaPa, and the
supernatants or the lysates were analysed by zymography as described in
Materials and methods. Molecular weights were determined using pre-
stained standards (Bio-Rad). CM: Conditioned Medium; L: lysates; 
C: concentrations 
Table 2 Effect of NaPa on u-PAR synthesis by MDA-MB-231, MCF-7 and MCF-7 ras 
Cell lines  NaPa (mM) 
0 1  2.5  5 10  20  ANOVA 
MDA-MB-231 5.3±0.61  6±0.56  5.5±0.31  7.7±0.82  8.2±0.61  8±0.46  P < 0.01 
MCF-7 0.52±0.06  0.54±0.01  0.6±0.23  0.81±0.24  0.95±0.21  0.62±0.05  NS 
MCF-7ras 0.41±0.03  0.36±0.05  0.44±0.08  0.51±0.13 0.48±0.11  0.4±0.13  NS 
u-PAR was measured by an ELISA in the lysates of the tumour cells. Cells were treated for 18 hours with NaPa for MDA-MB-231, and
for 3 days for MCF-7 and MCF-7 ras. Results are expressed as ng of u-PAR mg21 proteins. (Mean ± SEM of 3 separate experiments).
NS = non-significant. 
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Figure 4 Effect of increasing concentrations of NaPa on the adhesion of
MDA-MB-231, MCF-7 and MCF-7 ras on vitronectin. The tumour cells were
incubated for 18 hours in the presence of increasing concentrations of NaPa,
then detached by mild trypsination and washed twice with PBS. 2.5 ´ 105
cells were incubated for 3 hours in vitronectin coated wells, non-adherent
cells were removed by 2 washes in PBS. Adherent cells were quantified by
their acid phosphatase activity (see Materials and Methods) 806 M Vasse et al
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treatment of MDA-MB 231 cells with NaPa increased dose-
dependently the expression of both ICAM-1 and LFA-1, whereas
MAC-1 was unmodified (Figure 5A). When these cells were treated
for 3 days with NaPa, an increase of the 3 adhesion molecules was
observed, particularly pronounced for LFA-1. An increase of these 3
adhesion molecules was also observed on MCF-7 and MCF-7 ras,
but only after a 3 day treatment with NaPa (Figure 5C and D). 
Consequences of the increase of LFA-1 and ICAM-1 on
MDA-MB-231 invasiveness through Matrigel 
In order to analyse the involvement of the increased expression of
LFA-1 and ICAM-1 in MDA-MB-231 invasion through Matrigel,
we performed invasion assay using functional neutralizing anti-
bodies against these molecules. The decreased invasiveness of
MDA-MB-231 induced by 20 mM of NaPa was unmodified by the
pretreatment with a neutralizing mAb against ICAM-1 while the
pretreatment with the neutralizing mAb against LFA-1 partially
restores the invasiveness of the NaPa-treated cells (Table 3). 
DISCUSSION 
In this paper, we have shown that increasing concentrations of
NaPa strongly reduces the invasiveness of the highly invasive
MDA-MB-231 cell line. In order to analyse the mechanisms
involved in this inhibition, we firstly analysed the expression of 
u-PAR/u-PA system expressed by these cells and the secretion
of MMP-9, since these enzymes are known to facilitate cancer
cells invasion (Ossowski, 1992; Bianchi et al, 1994). By
comparing MDA-MB-231 to MCF-7 and MCF-7 ras cells we have
shown that this cell line expresses high levels of u-PA and secretes
MMP-9 in the conditioned medium. In addition only MDA-MB
231 cells secrete and express at their surface PAI-1 which is also
involved in cancer cell invasiveness (Bajou et al, 1998). These
data could explain why MDA-MB-231 cells are more tumorigenic
than MCF-7 and MCF-7 ras cells. Surprisingly, an 18 h incubation
of cancer cells with NaPa did not modify the expression of u-PA at
cell surface and even increased MMP-9 secretion and u-PAR
levels, while in the same conditions the invasiveness through
Matrigel was dramatically reduced. However when the incubation
with NaPa was prolonged for 3 days, a decrease in the expression
of u-PA was observed only on MDA-MB 231 cells and only for the
highest concentration of NaPa tested (20 mM). 
Since an increased cell adhesion could prevent the cell detach-
ment required for their invasiveness, we have investigated cancer
cell adhesion on fibronectin and vitronectin, a counterligand
of u-PAR, and the expression of LFA-1, ICAM-1 and MAC-1
(CD11b) which are frequently involved in the tumour cell adhe-
sion through the stromal tissue. An 18-h treatment of MDA-
MB-231 with NaPa greatly increased cell adhesion to vitronectin.
This result can be explained by the increased expression of u-PAR
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Figure 5 Effect of increasing concentrations of NaPa on the expression of
CD11b(MAC-1) (empty bars), ICAM-1 (grey bars) or LFA-I (hatched bars) of
MDA-MB -231 (A,B), MCF-7 (C), MCF-7ras (D). MDA-MB-231 were treated
either 18 hours (A) or 3 days (B) by NaPa, whereas MCF-7 and MCF-7 ras
were treated for 3 days. ICAM-1 and MAC-I were detected by flow cytometry
by direct immunofluorescence, whereas LFA-1 was detected by indirect
immunofluorescence, using a FITC-conjugated anti-mouse antibody. Data
are expressed as the percentage ( as compared to the controls) of the 
MFI ± S.E.M of 3 separate experiments
Table 3 Effect of neutralizing antibodies against ICAM-1 or LFA-1 on the decreased invasiveness through Matrigel of MDA-MB-231
treated for 18 hours by 20 mM of NaPa 
Controls  NaPa 20 mM  NaPa 20 mM + anti-ICAM-1  NaPa 20 mM+ anti LFA-1 
% of migrated cells  100  22.2 ± 4.5  28 ± 6.3  72.6 ± 8.5 
MDA-MB-231 were treated for 18 hours by 20 of NaPa. After trypsination and 2 washes in PBS, 23105 cells were incubated for 
30 mn at 4˚C with 100 mg of the neutralizing mAb before to be seeded in the upper chamber of the insert coated with Matrigel.
Controls were incubated with an irrelevant IgG1 antibody at the same concentration. After an 18 hour incubation at 37˚C, the cells
which had traversed the filter were counted by light microscopy after May-Grünewald coloration. 10 fields were counted for each
insert. Results are expressed as the percentage of migrated cells as compared to the controls. (Mean ± SEM of 2 separate
experiments.) Decrease of breast cancer cell invasiveness by NaPa 807
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on this cell line and this increased adhesivity was suppressed by
preincubating the cells with a monoclonal antibody against u-PAR
which blocks the interaction with vitronectin (Paysant et al, 1998).
This is also supported by the fact that NaPa did not modify the 
cell adhesion either on vitronectin nor on u-PAR of MCF-7 and
MCF-7 ras cells. 
Furthermore, the increased expression of LFA-1 is clearly
involved in the decreased invasiveness of MDA-MB-231 through
Matrigel, since a neutralizing antibody against this integrin
partially restores the invasive properties of MDA-MB-231 treated
by NaPa. The increase of ICAM-1, even if it is not related to the
decreased invasiveness of NaPa-treated MDA-MB-231 could be
of importance to explain the antitumoral activity of NaPa, since
this molecule can increase host cytotoxic responses against breast
tumour (Ogawa et al, 1998). In addition NaPa treatment increased
also the expression of MAC-1, another counterligand of ICAM-1,
but this increase was delayed as compared to the increase of LFA-
1 and ICAM-1. We have previously demonstrated that the cell–cell
adhesion of cancer cells was increased by NaPa treatment and that
this was explained in part by b cathenin phosphorylation (Thibout
et al, 1999). The increase by NaPa of LFA-1, MAC-1 and ICAM-
1 could also participate in the increased cell–cell adhesion and the
increased MMP-9 secretion since it was shown that cell adhesion
molecules regulate secretion of MMP (Edvardsen et al, 1993). 
NaPa treatment induced a shape change of MDA-MB-231 cells,
which adopted a spindle shape and detached from plastic. This
reorganization of the cytoskeleton, as well as the modifications
of cell–cell adhesion molecules could be responsible for the
increased MMP-9 secretion induced by NaPa since it was recently
reported that Paclitaxel treatment of breast cancer cells induces a
change in cytoskeleton organization associated with a concomitant
increase of MMP-9 secretion (Alonso et al, 1999). 
In conclusion, our results suggest that NaPa could affect the
complex interactions between ECM proteins and their receptors.
By increasing the expression of u-PAR and concomitantly the
adhesion to vitronectin, NaPa treatment might also contribute to
reduce breast cancer cell invasiveness of aggressive breast cancers
which contain high level of the u-PAR/u-PA system (Schmitt et al,
1997). Furthermore, the increase of LFA-1 induced by NaPa
contributes also to the decreased invasiveness of NaPa-treated
MDA-MB-231. The present results can explain our previous in
vivo studies showing that NaPa treatment in nude mice reduces the
breast tumour cell invasivity in stromal tissue (Adam et al, 1995).
Altogether, these results, with others, strongly suggest that NaPa
contributes to the reversibility of a highly invasive breast
phenotype by acting on the u-PAR system and on the ECM protein
adhesion systems. 
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